scientific programme
35
tuesday, 24 June 2014
Learning Objectives:
This symposium will
examing how basic and clinical findings are
contributing to our understanding of the cause
of, and potential interventions for, treatment
resistant depression which remains a signifi-
cant clinical problem.
S-17
SYMPOSIUM
15:00–17:00
Ballroom B
Track: Translational
Topic: Schizophrenia (A)
Novel glutamatergic treatment approach-
es for schizophrenia: Pharmacology, im-
aging and clinical trials
Chair:
Gerhard Gründer, Germany
Co-Chair: Dean F. Wong, USA
S-17-001
Challenges for novel treatment approaches
in schizophrenia
Gerhard Gründer, Germany
S-17-002
The pharmacological basis for novel gluta-
matergic treatments
Daniel C. Javitt, USA
S-17-003
Characterization of novel glutamatergic
treatments with PET imaging
Dean F. Wong, USA
S-17-004
Clinical results with novel glutamatergic
treatments
Daniel Umbricht, Switzerland
Learning Objectives:
This symposium will
give a broad overview on the potential for
drugs targeting the glutamatergic system to
be used as a treatment for schizophrenia.
S-18
SYMPOSIUM
15:00–17:00
Ballroom C
Track: Translational
Topic: Post-traumatic stress disorder (A)
Breakthroughs in psychopharmacology
for prevention and treatment of PTSD
Chair:
Eric Vermetten, The Netherlands
Co-Chair: Joseph Zohar, Israel
S-18-001
Three decades of research in circuits and
receptor systems in PTSD
Eric Vermetten, The Netherlands
S-18-002
New insights into secondary prevention in
PTSD
Joseph Zohar, Israel
S-18-003
Update on the use of alpha-1 adrenoreceptor
antagonists for PTSD
Murray Raskind, USA
S-18-004
Does the endocannabinoid system provide
a new avenue for treatment development
in PTSD?
Alexander Neumeister, USA
Learning Objectives:
In this symposium del-
egates will learn of breakthroughs in the pre-
vention and treatment of PTSD.
S-19
SYMPOSIUM
15:00–17:00
Room 11
Track: Translational
Topic: Biomarkers (including pharmacoge-
nomics and brain imaging) for diagnosis
and treatment response (C)
The psychopharmacology of aggression:
From biomarkers to therapeutics
Chair:
Gabriella Gobbi, Canada
Co-Chair: Klaus-Peter Lesch, The Nether-
lands
S-19-001
Genetic determinants in aggression
Klaus-Peter Lesch, The Netherlands
S-19-002
Biomarkers in aggressive behavior
Stefano Comai, Canada
A. Bertazzo, J. Vachon, G. Côté, G. Gobbi
S-19-003
Mood stabilizers in aggression: Basic and
clinical research
Gabriella Gobbi, Canada
S-19-004
Atypical antipsychotics for the management
of agitation and aggression: An update
Leslie Citrome, USA
Learning Objectives:
The control of aggres-
sion can be a significant clinical problem and
the potential causes and treatment of agression
will therefore be reviewed in this symposium.
